The price reduction for Aduhelm (aducanumab) comes into play from 1 January and comes on the back of the “feedback of our stakeholders,” said the biotech’s chief executive Michel Vounatsos.
“Too many patients are not being offered the choice of Aduhelm due to financial considerations,” he added.
The timing of the price cut has raised a few eyebrows, coming ahead of the review by the Center for Medicare and Medicaid Services (CMS) into reimbursement which is expected to deliver a verdict in mid-January.
